Medline falls as backers slice stakes in $2.1 bln secondary offering

By Reuters News

** Medical-surgical supplies giant Medline's MDLN.O shares down 3.4% at $36.39 before the bell after ~$2.1 bln secondary offering priced

** MDLN late Weds announced sale of 60 mln shares by stockholders Blackstone BX.N, Carlyle Group CG.O, Hellman & Friedman (H&F), GIC Private and Abu Dhabi Investment Authority (ADIA) at $35.50

** Offering price represents 5.8% discount to stock's last sale of $37.68 on Tues

** MDLN shares closed at $39.47 on Fri; MDLN launched the offering early Mon

** Private equity sponsors BX and H&F selling ~19 mln shares each, CG offloading ~9.5 mln; GIC and ADIA offering ~9.3 mln ~3.1 mln shares, respectively, per the prospectus

** Also, MDLN agreed to repurchase $200 mln of shares and partnership interests from selling shareholders in private transaction

** Goldman Sachs, Morgan Stanley, BofA and JP Morgan leading public offering

** Through Tues, stock gained 17% in Nov, leaving it down ~10% YTD

** Northfield, Illinois-based MDLN went public last Dec in over $6 bln IPO priced at $29

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.